Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News WPD Pharmaceuticals Inc C.WBIO

Alternate Symbol(s):  WPDPF

Industrials Technology
WPD Pharmaceuticals Inc. is a Canada-based clinical-stage pharmaceutical company, with a focus on glioblastoma cancer (GBM) and other brain tumor programs. The Company is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. It has four novel drug candidates with one in... see more

Recent & Breaking News (CSE:WBIO)

WPD Pharmaceuticals Invited to Join International Research Consortium

GlobeNewswire June 10, 2021

WPD Pharmaceuticals Provides Update on Audited Financial Statements

GlobeNewswire May 14, 2021

WPD Pharmaceuticals to Receive $6.7 Million Grant for Development of Annamycin Drug Candidate

GlobeNewswire May 11, 2021

WPD Pharmaceuticals Receives Approval for Temporary Management Cease Trade Order for Late Filing of Audited Annual Financial Statements

GlobeNewswire May 5, 2021

WPD Pharmaceuticals (CSE:WBIO) applies for a management cease trade order

Brieanna McCutcheon  April 29, 2021

WPD Pharmaceuticals Announces Application for a Management Cease Trade Order For Late Filing of Audited Annual Financial Statements

GlobeNewswire April 29, 2021

WPD Pharmaceuticals (CSE:WBIO) to attend the 10th congress of the Polish Society of Pediatric Oncology and Hematology

Brieanna McCutcheon  April 27, 2021

WPD Pharmaceuticals to Attend the 10th Congress of the Polish Society of Pediatric Oncology and Hematology and Present Assumption of the Phase 1 Study with Berubicin in Pediatric Malignant Gliomas

GlobeNewswire April 27, 2021

WPD Pharmaceuticals (CSE:WBIO) and IAG to host a webinar about the effects of Berubicin in brain cancer

Brieanna McCutcheon  April 13, 2021

WPD Pharmaceuticals and IAG to Host a Joint Webinar, "The Potential of Advanced Imaging to Show the Early Treatment Effects of Berubicin in Brain Cancer"

GlobeNewswire April 13, 2021

WPD Pharmaceuticals Holds Pre-Submission Meeting with the European Medicines Agency and Receives Second Prepayment of C$954,248 From a Total C$7.4 Million Grant for Development of Berubicin

GlobeNewswire April 6, 2021

WPD Pharmaceuticals (CSE:WBIO) amended sublicense agreement with Moleculin Biotech

Brieanna McCutcheon  March 30, 2021

WPD Pharmaceuticals Announces Amended Sublicense Agreement with Moleculin Biotech for WP1066, WP1122 and Annamycin Drug Candidates

GlobeNewswire March 30, 2021

WPD Pharmaceuticals Engages World-Renowned Paediatric Oncology Expert to Support Glioblastoma Programs for WPD101

GlobeNewswire March 16, 2021

WPD Pharmaceuticals (CSE:WBIO) signs new agreement with CNS Pharmaceuticals

Brieanna McCutcheon  February 24, 2021

WPD Pharmaceuticals Announces Berubicin Supply Agreement for the Upcoming Clinical Trials

GlobeNewswire February 24, 2021

WPD and CNS Pharmaceuticals Announce Positive Opinion of the Polish Central Ethics Committee for the WPD-201 Study and Central IRB Study Level Approval for the CNS-201 Study

GlobeNewswire February 18, 2021

WPD Pharmaceuticals (CSE:WBIO) engages Worldwide for clinical trials

Brieanna McCutcheon  February 11, 2021

WPD Pharmaceuticals Engages Worldwide Clinical Trials as CRO for Further Support on Berubicin Trials

GlobeNewswire February 11, 2021

WPD Pharmaceuticals Announces US$1.5M Grant Awarded to Polish Research Institute for Independent Clinical Trial of Annamycin

GlobeNewswire February 9, 2021